Trials / Completed
CompletedNCT00267930
Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter Recurrence
A Pilot Phase II, Randomised, Double-Blind, Placebo-Controlled, Multi-Centred Safety, Tolerability and Preliminary Efficacy Study of RSD1235-SR for the Prevention of Atrial Fibrillation/Atrial Flutter (AF/AFL) Recurrence in Subjects Post-Conversion Form AF
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 221 (actual)
- Sponsor
- Advanz Pharma · Industry
- Sex
- All
- Age
- 18 Years – 85 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the safety, tolerability and preliminary efficacy of vernakalant (oral) in subjects with sustained atrial fibrillation of greater than 72 hours and less than 6 months duration
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Vernakalant (oral) | |
| DRUG | Placebo comparator |
Timeline
- Start date
- 2005-12-01
- Completion
- 2006-08-01
- First posted
- 2005-12-22
- Last updated
- 2008-12-18
Locations
22 sites across 4 countries: United States, Canada, Denmark, Netherlands
Source: ClinicalTrials.gov record NCT00267930. Inclusion in this directory is not an endorsement.